Related Experiment Video
Updated: Jan 22, 2026

Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis
Published on: July 28, 2023
Minimizing missed latent tuberculosis infection under adalimumab: real-world data from a BCG-vaccinated cohort
Fatma Merve Koçak1, Berru Yargı Özkoçak2
1Department of Infectious Diseases and Clinical Microbiology, Beyoğlu Eye Training and Research Hospital, Istanbul, Turkey. drmervekocak@gmail.com.
Background:
Tumor necrosis factor-alpha (TNF-α) inhibitors, particularly adalimumab (ADA), are widely used for ocular inflammatory diseases but may increase the risk of tuberculosis reactivation. Data on latent tuberculosis infection (LTBI) screening and outcomes are limited. This study aimed to describe LTBI screening outcomes in ADA-treated uveitis and identify patterns of missed cases.
Methods:
A total of 188 patients evaluated for ADA eligibility between December 2021 and April 2025 were retrospectively analyzed. LTBI screening included medical history, tuberculin skin test (TST), interferon-gamma release assay (IGRA), or both. Isoniazid prophylaxis was given when indicated, and tuberculosis occurrence during ADA was assessed.
Results:
Among 188 patients (mean age 40.3 ± 14.2 years), Behçet's uveitis (39.7%) and sarcoidosis (23.9%) were the most common. TST alone was used in 60.2%, IGRA in 13.4%, and both in 26.3% among those with baseline testing. TST and IGRA results were significantly associated (p = 0.001). INH prophylaxis rates varied by screening method (p = 0.003). Tuberculosis occurred in 1.6% (n = 3), including two despite prophylaxis.
Conclusion:
LTBI screening and prophylaxis reduce but do not eliminate TB risk under ADA. Combined TST/IGRA and periodic re-evaluation may reduce missed cases in BCG-vaccinated populations.
Related Concept Videos
Vaccinations
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:

